{
    "nct_id": "NCT04999969",
    "official_title": "A Phase II Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumours",
    "inclusion_criteria": "* Eastern Cooperative Oncology Group performance status of 0 or 1 at screening/enrolment\n* Must have a Gustave Roussy Immune Score of 0 or 1\n* Participants diagnosed with histologically confirmed metastatic pancreatic adenocarcinoma\n* Participants must have at least 1 measurable lesion to be called a target lesion according to RECIST v1.1\n* All participants must consent to providing sufficient archival specimen taken during metastatic stage or fresh tumour specimens for tumoural CD8+ T cell testing for enrolment\n* Presence of tumoural CD8+ T cells based on a predetermined benchmarked PDAC external sample\n* Normal organ and bone marrow function measured within 28 days prior to first dose of study intervention\n* Body weight ≥ 35 kg\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 130 Years",
    "exclusion_criteria": "* Symptomatic central nervous system metastasis or any history of leptomeningeal disease or cord compression\n* A participant with an already known sensitising mutation or tumour characteristic for pancreatic cancer for which there is a preferred local standard-of-care treatment\n* History of thromboembolic event within the past 3 months prior to the scheduled first dose of study intervention\n* Any unresolved toxicities ≥ Grade 2 per Common Terminology Criteria for Adverse Events v5.0 from prior therapy (excluding vitiligo, alopecia, controlled diabetes)\n* History of solid organ transplantation\n* History of active primary immunodeficiency\n* Ongoing or an active infection, including tuberculosis, hepatitis B, hepatitis C, or human immunodeficiency virus. A negative COVID-19 PCR test taken within 28 days of the start of the study treatment is required.\n* Uncontrolled intercurrent illness\n* Participants with prior history of myocardial infarction, transient ischemic attack, coronary bypass, or stroke within the past 3 months prior to the first dose of study intervention\n* Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥470 ms calculated from 3 electrocardiograms\n* Active or prior documented autoimmune or inflammatory disorders\n* History of another primary malignancy\n* Receipt of any conventional or investigational anticancer therapy prior to the scheduled first dose of study intervention\n* Prior receipt of any immune-mediated therapy\n* Use of immunosuppressive medication within 14 days prior to the first dose of study intervention\n* Receipt of live, attenuated vaccine within 28 days prior to the first dose of study intervention (Participants can receive non-live COVID-19 vaccines, at the discretion of the Investigator)",
    "miscellaneous_criteria": ""
}